Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas

Peking University Cancer Hospital & Institute100 enrolled

Overview

Investigating the performance of 18F-FDG PET/CT and PET/MRI in lymphomas

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by 18F-FDG PET (PET/CT and PET/MR). Prior to treatment, all patients will undergo whole-body 18F-FDG PET/CT and PET/MR. The methods' efficiency was compared in the diagnosis of lymph node (LN) and organ involvement.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

PET/MRI

Eligibility

Sex: ALLMin age: 15 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * pathologically diagnosed as lymphoma; Written informed consent for receiving PET/MRI after PET/CT examinations. cancer planned chemotherapy or immunotherapy scheme. expected survival ≥ 12 weeks Exclusion Criteria: * cannot lie supine for half an hour; refuse to join the clinical researcher; severe liver or kidney dysfunction pregnancy or lactation

Locations (1)

Peking University Cancer Hospital

Beijing, Card Holder's Billing State / Province, China

RECRUITING

Outcomes

Primary Outcomes

SUVmax

Standardized uptake value of 18F-FDG PET/CT and PET/MRI for target lesion of subject or suspected tumor in each time point window (SUV)

Time frame: 150 days

Central Contacts

Xuejuan Wang, MD

CONTACT

86 010 88196363 xuejuan_wang@hotmail.com

Zhi Yang, PhD

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.